CoChat

Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes

Pan, J., Lin, M., Kesala, R. L., Van, J., Charles, M. A. · 2002 · Diabetes, Obesity and Metabolism
Cited by 66

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Objective: We tested the hypotheses that niacin is effective for the separate treatments of abnormalities of LDL particle size, HDL2 percentage and Lp(a) without potential negative effects on glycated haemoglobin. Research Design and Methods: The atherogenic lipid profile lipids, such as triglycerides, small, dense LDL cholesterol (LDLc) particle mass, LDL particle size, total HDLc and HDL2 percentage as well as Lp(a), were measured in 42 diabetic patients with abnormalities of LDL particle size, HDL2 percentage and/or Lp(a) levels before and after niacin treatment. LDL particle size and HDL2 were measured using polyacrylamide gradient gel electrophoreses and Lp(a) was measured by enzyme‐linked immunoabsorbance assay (ELISA). Results: After niacin treatment, LDL peak particle diameter increased from 252 ± 7 Å to 263 ± 7 (p < 0.0001), small, dense LDLc particle mass decreased from 27 ± 11 mg/dL to 15 ± 4 (p < 0.0001), total HDLc increased from 39 ± 7 mg/dL to 51 ± 11 (p < 0.0001), HDL2 as the percentage of total HDLc mass increased from 29 ± 8% to 45 ± 10 (p < 0.0001) and Lp(a) decreased from 43 ± 17 mg/dL to 25 ± 10 (p < 0.0001). Mean haemoglobin A1c level was improved during treatment from 7.6 ± 1.8% to 6.5 ± 1.0 (p < 0.0001) using increased oral agent and insulin treatment doses in more than 90% of the patients. A total of 21% of the patients were unable to tolerate niacin owing to reversible side‐effects, and 14% were unable to adhere to the niacin dosing regimen of three times daily. Conclusions: These data indicate that in diabetic patients, niacin (i) is effective for treating diabetic dyslipidaemias associated with both the atherogenic lipid profile and Lp(a); (ii) must be used with modern and aggressive oral hypoglycaemic agents or insulin treatment; and (iii) is an important drug to treat diabetes dyslipidaemias because of its broad spectrum of effectiveness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1463-1326.2002.00205.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 66

Metadata

Authors
Pan, J., Lin, M., Kesala, R. L., Van, J., & Charles, M. A.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2002-07
Volume
4
Issue
4
Pages
255-261
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1978318375
Cited by
66
References
4
FWCI
4.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. https://app.cochat.ai/papers/10.1046/j.1463-1326.2002.00205.x
The paper
Pan, J., Lin, M., Kesala, R. L., Van, J., & Charles, M. A. (2002). Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1046/j.1463-1326.2002.00205.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.